COVID-19 in patients with hematologic malignancy
P Langerbeins, M Hallek - Blood, The Journal of the American …, 2022 - ashpublications.org
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-
2 have been approved for at least limited use, with over sixty others in clinical trials. This …
2 have been approved for at least limited use, with over sixty others in clinical trials. This …
Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer
Importance As the COVID-19 pandemic continues, understanding the clinical outcomes of
patients with cancer and COVID-19 has become critically important. Objective To compare …
patients with cancer and COVID-19 has become critically important. Objective To compare …
[HTML][HTML] Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer …
Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
[HTML][HTML] Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity,
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
[HTML][HTML] COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
L Wang, NA Berger, PB Davis, DC Kaelber, ND Volkow… - MedRxiv, 2022 - ncbi.nlm.nih.gov
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …
Increased risk for COVID‐19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and …
L Wang, QQ Wang, PB Davis, ND Volkow… - World …, 2022 - Wiley Online Library
Individuals with substance use disorders (SUDs) are at increased risk for COVID‐19
infection and for adverse outcomes of the infection. Though vaccines are highly effective …
infection and for adverse outcomes of the infection. Though vaccines are highly effective …
Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative
Q Song, B Bates, YR Shao, FC Hsu, F Liu… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide real-world evidence on risks and outcomes of breakthrough COVID-
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
Outcomes of COVID-19 in patients with cancer: report from the National COVID Cohort Collaborative (N3C)
PURPOSE Variation in risk of adverse clinical outcomes in patients with cancer and COVID-
19 has been reported from relatively small cohorts. The NCATS'National COVID Cohort …
19 has been reported from relatively small cohorts. The NCATS'National COVID Cohort …